CIAM
ACAD icon

Caitong International Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Caitong International Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,534
Closed -$42.1K – 1944
2025
Q1 		$42.1K Sell
2,534
-7,217
-74% -$131K 0.03% 551
2024
Q4 		$179K Buy
+9,751
New +$157K 0.18% 105

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Caitong International Asset Management's ACAD Position: Q2 2025 in Review

Caitong International Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 2,534 shares — an estimated $42.1K sold.

Caitong International Asset Management first reported a position in ACAD in Q4 2024 and held it in 2 quarters. The position peaked at $179K in Q4 2024. 310 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Caitong International Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 2,534 Acadia Pharmaceuticals shares in Q2 2025, an estimated $42.1K.
  • Caitong International Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Caitong International Asset Management's Acadia Pharmaceuticals position peaked at $179K in Q4 2024.
  • 310 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Caitong International Asset Management's 13F filing for Q2 2025, filed 31 Jul 2025.